IJIMS.2016.110

Type of Article: Original Research

Volume 3; Issue 3: March 2016

Page No.: 253-256

DOI: 10.16965/ijims.2016.110

 

Clinical Profile of Mucormycosis: A Study from Teaching Hospital in North Karnataka, India

Rajoor UG *1, Mahabalshetti AD 2, Dhananjaya M 3.

*1 Associate Professor, Department of Medicine, Koppal Institute of medical sciences, Koppal, State-Karnataka, India.

2 Associate Professor, Department of Medicine, SDM College of medical sciences and hospital, Sattur, Dharwad, State-Karnataka, India.

3 Assistant Professor, Department of Medicine, SDM College of medical sciences and hospital, Sattur, Dharwad, State-Karnataka, India.

CORRESPONDING AUTHOR ADDRESS: Dr. Amrut Mahabalshetti, Associate Professor, Department of Medicine, SDM College of medical sciences and hospital, Sattur, Dharwad-580009, State-Karnataka, India. E-Mail: amrutdm@gmail.com

ABSTRACT

Background and objectives: Mucormycosis is a relatively rare opportunistic fungal infection. It is one of the devastating infections of immunocompromised host. Though several studies were done in India and elsewhere on Mucormycosis, it has not been extensively studied of late. The objective of the study is to study the clinical profile of Mucormycosis in the northern part of Karnataka.

Materials and Methods: Our series compromised of 14 cases seen over a period of 5 years. Detailed history, clinical examination, laboratory investigations were carried out in all the cases.

Results: The study group consisted of 10 males and 4 females aged 20 – 70 years (mean 50 years). Most of the patients in the study group had evident blackish nasal eschar and sinus disease. Cultures were positive for Mucorales in 08 cases. 11 patients were treated with amphotericin B in the doses ranging from 0.5 – 1.0 mg/kg up to a total of 2.6 grams, and duration of the treatment varied from 1 – 31 days.

Conclusions: Mucormycosis is a rare opportunistic fungal infection with rapidly progressive and fulminant course with often fatal outcome. A strong suspicion, prompt diagnosis with pathological confirmation and aggressive surgical treatment gives a better outcome.

Key words: Mucormycosis, Fungal, Amphotericin.

REFERENCES

  1. Torres-Narbona M, Guinea J, Munoz P, Bouza E. Zygomycetes and zycomycosis in the new era of antifungal therapies. Rev Esp Quimioter 2007;20:375-86.
  2. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zycomycosis: the re-emerging fungal infection. Eur J Clin Microbiolog Infect Dis 2006;25:215-29.
  3. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiolog Infect 2010; 10(suppl 1): 31-47.
  4. Talmi YP, Reouven AG, Bakon M, Barshack I, Wolf M, Horowitz Z et.al. Rhino-orbital and rhino-orbito-cerebral Mucormycosis. Otolaryngol Head Neck Surg 2002; 127: 22-31.
  5. Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, Mariani U. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature 2011;11:e533-540.
  6. Baker RD. The phycomycoses. Anna N Y Acad Sci 1970; 174: 592-605.
  7. Morduchowicz G, shmueli D, Shapira Z et al. Rhinocerebral Mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis 1986;8:441-6.
  8. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbito-cerebral Mucormycosis. Surv ophthalmo 1994;39:3-22.
Download Full Text TOC